Figure 1.

Wnt3a stabilizes β-catenin in MM cell lines and primary MM plasma cells. The myeloma cells were treated with Wnt3a-CM or Cont-CM for the indicated time (A). Primary CD138-selected plasma cells from 6 patients with MM confirmed by flow cytometry analysis were treated with Wnt3a-CM or Cont-CM for 3 hours (B). Proteins isolated from the above-treated cells were subjected to Western blotting analysis as described in “Wnt3a stabilizes β-catenin in MM cells.” Total β-catenin was determined by using an antibody that recognized the protein. The vertical lines have been inserted to indicate different gels used.